These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12975380)

  • 41. Lifetime and recent alcohol use and bone mineral density in adults with HIV infection and substance dependence.
    Ventura AS; Winter MR; Heeren TC; Sullivan MM; Walley AY; Holick MF; Patts GJ; Meli SM; Samet JH; Saitz R
    Medicine (Baltimore); 2017 Apr; 96(17):e6759. PubMed ID: 28445303
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bone Loss in HIV Infection.
    Moran CA; Weitzmann MN; Ofotokun I
    Curr Treat Options Infect Dis; 2017 Mar; 9(1):52-67. PubMed ID: 28413362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bone mineral density and vitamin D concentration: the challenges in taking care of children and adolescents infected with HIV.
    Carmo FB; Terreri MT; Succi RCM; Beltrão SV; Gouvea AFTB; Paulino ERC; Machado DM
    Braz J Infect Dis; 2017; 21(3):270-275. PubMed ID: 28399423
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The protease inhibitors and HIV-associated bone loss.
    Moran CA; Weitzmann MN; Ofotokun I
    Curr Opin HIV AIDS; 2016 May; 11(3):333-42. PubMed ID: 26918650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transforming growth factor-β1-mediated cardiac fibrosis: potential role in HIV and HIV/antiretroviral therapy-linked cardiovascular disease.
    Ahamed J; Terry H; Choi ME; Laurence J
    AIDS; 2016 Feb; 30(4):535-42. PubMed ID: 26605511
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hemin activation of innate cellular response blocks human immunodeficiency virus type-1-induced osteoclastogenesis.
    Takeda K; Adhikari R; Yamada KM; Dhawan S
    Biochem Biophys Res Commun; 2015 Aug; 464(1):7-12. PubMed ID: 25998388
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection.
    Byrne DD; Newcomb CW; Carbonari DM; Nezamzadeh MS; Leidl KB; Herlim M; Yang YX; Hennessy S; Kostman JR; Leonard MB; Localio AR; Lo Re V
    J Viral Hepat; 2015 Nov; 22(11):936-47. PubMed ID: 25754215
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of Blood Biomarkers of Bone Turnover in HIV-1 Infected Individuals Receiving Anti-Retroviral Therapy (ART).
    Aziz N; Butch AW; Quint JJ; Detels R
    J AIDS Clin Res; 2014; 5():. PubMed ID: 25705563
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.
    Kelesidis T; Currier JS; Yang OO; Brown TT
    AIDS Rev; 2014; 16(3):123-33. PubMed ID: 25102334
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study.
    Hileman CO; Labbato DE; Storer NJ; Tangpricha V; McComsey GA
    AIDS; 2014 Jul; 28(12):1759-67. PubMed ID: 24871454
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Elevated suppressor of cytokine signaling-1 (SOCS-1): a mechanism for dysregulated osteoclastogenesis in HIV transgenic rats.
    Lafferty MK; Fantry L; Bryant J; Jones O; Hammoud D; Weitzmann MN; Lewis GK; Garzino-Demo A; Reid W
    Pathog Dis; 2014 Jun; 71(1):81-9. PubMed ID: 24376119
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV and Bone Disease: A Perspective of the Role of microRNAs in Bone Biology upon HIV Infection.
    Del Carpio-Cano FE; Dela Cadena RA; Sawaya BE
    J Osteoporos; 2013; 2013():571418. PubMed ID: 24286015
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis.
    Weitzmann MN
    Scientifica (Cairo); 2013; 2013():125705. PubMed ID: 24278766
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142.
    Huang JS; Hughes MD; Riddler SA; Haubrich RH;
    HIV Clin Trials; 2013; 14(5):224-34. PubMed ID: 24144899
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients.
    Aydın OA; Karaosmanoglu HK; Karahasanoglu R; Tahmaz M; Nazlıcan O
    Braz J Infect Dis; 2013; 17(6):707-11. PubMed ID: 24076108
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.
    Gill AJ; Kolson DL
    Crit Rev Immunol; 2013; 33(4):307-59. PubMed ID: 23971529
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Accelerated Aging in HIV Patients.
    Meir-Shafrir K; Pollack S
    Rambam Maimonides Med J; 2012 Oct; 3(4):e0025. PubMed ID: 23908849
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study.
    Bonnet E; Ruidavets JB; Genoux A; Mabile L; Busato F; Obadia M; Prévoteau F; Marchou B; Massip P; Marion-Latard F; Delpierre C; Bernard J; Perret B
    BMC Infect Dis; 2013 Jun; 13():293. PubMed ID: 23809140
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bone health in children and adolescents with perinatal HIV infection.
    Puthanakit T; Siberry GK
    J Int AIDS Soc; 2013 Jun; 16(1):18575. PubMed ID: 23782476
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bone and vitamin D metabolism in HIV.
    Panayiotopoulos A; Bhat N; Bhangoo A
    Rev Endocr Metab Disord; 2013 Jun; 14(2):119-25. PubMed ID: 23657562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.